ReviewVideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy2025
Tumor enhancement by magnetic resonance imaging after endoscopic ultrasound-guided radiofrequency ablation for small pancreatic neuroendocrine tumors.
Review in VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA): Are We Getting Evidence-Based Results? A Systematic Review According to the Levels of Evidence.Medicina (Kaunas, Lithuania) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Pancreatic neuroendocrine tumors (PNETs) are rare and often diagnosed at advanced stages, limiting curative options. For PNETs <20 mm, endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has emerged as a minimally invasive therapeutic alternative. This study investigates the role of magnetic resonance imaging (MRI) in monitoring postablation enhancement, emphasizing its utility in assessing treatment efficacy. Methods: Four PNETs in the uncinate process, measuring <15 mm, underwent EUS-RFA (insulinomas [2 patients]; nonfunctioning PNETs [2 patients]). MRI was performed immediately (2 patients) and 30 days (2 patients) after EUS-RFA to confirm tumor destruction, with enhancement analysis as the main marker of effective ablation. Results: The diagnostic confirmation of all PNETs was obtained through EUS fine-needle biopsy before EUS-RFA. One insulinoma required 2 sessions (25%), whereas the other 3 needed only 1 EUS-RFA session (75%). All 5 sessions were technically successful (100%) and clinically effective in 75% of cases after a single application. Mild duodenal bleeding was observed in case 4 (20%). MRI demonstrated complete destruction of the nodules in all cases. Conclusions: EUS-RFA is a safe, well-tolerated, and effective treatment for both functioning and nonfunctioning PNETs <20 mm. It offers a minimally invasive alternative for patients unfit for or unwilling to undergo surgery or active surveillance. MRI proved valuable in assessing postablation tumor vascular enhancement.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.